ZS Pharma, Inc. Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: San Mateo CA United States (2008)
Status: Acquired by AstraZeneca (2015)

Organization Overview

First Clinical Trial
2011
NCT01493024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

cellulose (2 trials)

sodium polystyrene sulfonate (kayexalate) (1 trial)

Drugs in Phase 3 Trials (1)

zirconium silicate (Lokelma) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperkalemia (Phase 4)

Kidney Diseases (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 3